Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Samuel B. Weidner
Institution:
Flatiron Health (United States)
Observed institutions:
Tufts Medical Center,
Flatiron Health (United States)
ORCID:
0000-0002-3696-0113
Observed ORCID:
0000-0002-3696-0113
OpenAlex ID:
A5003528139
Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions
2022
·
Tara A. Lavelle
, Xue Feng
, et al.
·
Genetics in Medicine
·
72
PDF
Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions
2022
·
Tara A. Lavelle
, Xue Feng
, et al.
·
Genetics in Medicine
·
14
391 Value estimation of the Diabetes Prevention Program: How well does clinical trial-based cost-effectiveness apply to the real world?
2024
·
Natalia Olchanski
, Samuel B. Weidner
, et al.
·
Journal of Clinical and Translational Science
·
1
PDF
Estimating the Risk-Based Value of the Diabetes Prevention Program: How well does clinical trial-based cost-effectiveness apply to the real world?
2025
·
Natalia Olchanski
, Samuel B. Weidner
, et al.
·
medRxiv
PDF
Response to Grosse and Gudgeon
2022
·
Tara A. Lavelle
, Xue Feng
, et al.
·
Genetics in Medicine
The cost of business restrictions during the COVID-19 pandemic
2021
·
Joshua T. Cohen
, Samuel B. Weidner
·
F1000Research
Show more works
View as search
Works count:
6
Citation count:
86
H-index:
2
I10-index:
2
Year
Topic
Type
